Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANQUILITY: Reproxalap in Dry Eye Disease
NCT04674358Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing Reproxalap 0.25% with Vehicle (2 arms). Primary endpoint: Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber at Day 2. Started Nov 2020; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04674358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674358.